Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market
A year after Novartis wagered $9.7 billion on The Medicines Company and its PCSK9 drug, inclisiran is set for its first launch.
The EU …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
